Info on Biel 3/27/2018 Approved For Payment On The UK's NHS TARIFF LIST: IXA BioElectronics Corporation Pulsed electromagnetic stimulator ActiPatch device back 1 device 1395 35251411000001101
So forget about boots lets just talk about LLoyds , 1500 location,
at least 5 people vist for pain daily , x 1500 locations x $20 x 30 days = $4,500,000 monthly... that is us forgetting everyone other place that sells it .. ======2.5 people per/day $2,250.000 monthly sales ======1 person per/day $900K monthly sales
Keep in mind partners are happening and licensed ones at that.
The back study will not go in as a new submission, it is included in the knee and ankle submission so this will happen quicker than most would believe. Well actually the back study will be added to the prior submission, I don't want to confuse you
Watch how huge the Co-Branding gets. How many names besides Pain Gear?
Increasing shareholder value=7 components of shareholder value.
• Revenue
• Operating Margin
• Cash Tax Rate
• Incremental Capital Expenditure
• Investment in Working Capital
• Cost of Capital
• Competitive Advantage Period
Within the next 120 days BIEL will have in place-
Full body clearance minus the Migraine, anticipated clearance at a later date based upon the fact that this is a preventative study and the patients must have signs of a migraine coming, this study is a little more complicated.
Licensed partners (Major)
Equity partners
At least 2 huge retail chains
Let’s add on a few more distributors. Why not? Lol
NHS-first week of April, keep in mind not the only week, this is lifetime!
There will be other EU States that will duplicate the NHS and this will be coupled with licenses being sold to partners. What price, how much in royalties will soon be determined.
The August financials will and should be the strength of evidence that a certain person has established a supply chain that will be second to none.
I should mention that sales makeup only one component of the revenue stream, this is where my opinion may differ from the good posters on the BIEL board.
Revenue is the total amount taken in by a business in a set period of time.
This can include royalties, license fees and equity from partners and sales.
BIEL cannot have millions in sales without including the other revenue streams mentioned above.
My revenue forecast including sales may be different than others.
Great rewards will follow in due time. Waiting on the FDA protocol. Which means pre-submission. Guidance, rules and timing will be part of the protocol.(Looks like May-June clearance.)
Migraine clinical results will still be the huge one for the FDA protocol.(August-September clearance on positive results.)
NHS is the first of many EU States getting on board. Pretty good health systems across the pond. Sweden next!
The back pain study will obtain US FDA clearance for relief of musculoskeletal pain. Migraine headaches are not musculoskeletal. Migraines and musculoskeletal pain are both neurological disorders. Two FDA clearances!!!!!!!!!!!!!
SEC-much ado about nothing!
Partners-much ado about something!
12/7/2017 - Try and Tell US Launch, gets a 7 Day ActiPatch to US residents for shipping and handling costs of $4.95
12/7/17 - BIEL closes a deal with ANDA for National Distribution, ANDA has 60,000 commercial customers and is owned by TEVA Pharma, TEVA has extensive business dealings with the NHS
1/4/2018 - ActiPatch gains admission to the UK NHS Drug Tariff as a covered medical device, The NHS is the largest single healthcare delivery organization in the world
1/9/2018 - CARE Pharmacies will be handling the ActiPatch, CARE is an organization of 90 pharmacies in 17 states, CARE will be educating patients on the benefits of drug-free pain relief through Pain Consultations
1/16/2018 - Allay Menstrual Clinical Study is fully enrolled, taking place at the prestigious Birmingham Women's Hospital,an NHS Foundation Hospital
1/22/2018 - BIEL signs deal with MundiPharma in Australia and 8 other countries, Mundi is associated with Purdue Pharma, KN interview
1/22/2018 - Back Pain Study is complete, BIEL has dialogue ongoing with FDA for submission of Study to expand ActiPatch indications, KN interview
1/22/2018 - Migraine Study will get the full attention of staff now that the Back Study has been completed
1/22/2018 - BIEL in talks with Walmart
1/22/2018 - Meeting scheduled with CVS
This is the last 2 months of activity for BIEL. Any other OTC company would be dancing in the Street if they had accomplished this much in the last year.
The NHS Approval has opened new doors for BIEL and will continue to do so for many years.
BioElectronics ActiPatch Drug-Free Pain Therapy Receives United Kingdom National Health System Payment Coverage January 04, 2018 07:00 ET | Source: BioElectronics Corporation
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government-funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half of the 50 million UK adults may be living with chronic-pain¹, which is why there are more than 100,000 physician visits every day for musculoskeletal pain alone².
The ActiPatch is a drug-free, wearable medical device that regulates peripheral nerve activity to provide pain relief. The NHS based its decision considering strong clinical evidence and a health economics study, which found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere,” said Keith Nalepka, VP of Sales & Marketing at BioElectronics.
With the addition of ActiPatch to list of approved treatments, chronic pain sufferers now have access to paid safe, drug-free chronic pain relief. The ActiPatch will be listed for payment coverage in April.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
This improvement translated into reduced utilization of healthcare services, leading to a 36.8% reduction in health care costs to the NHS over a 3-month period, even after accounting for the cost of the ActiPatch device
Conclusion Utilizing ActiPatch® as a chronic pain therapy treatment improves patient quality of life, while reducing the economic burden to the NHS.
Almost half of all UK adults may be living with chronic pain "Almost half the adult population is living with chronic pain," the Daily Mail reports. A major new review suggests that around 28 million adults in the UK are affected by some type of chronic pain (pain that lasts for more than three months). Read More Link https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pain/
February 06, 2017 09:05 ET
BioElectronics Corporation Announces US FDA OTC Clearances For Drug-free ActiPatch® Musculoskeletal Pain Therapy FREDERICK, MD--(Marketwired - Feb 6, 2017) - BioElectronics Corporation (OTC PINK: BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:
Impressive Efficacy No harmful side effects A 50% Reduction in Medication Use, including opioidsExceptional Consumer Acceptance Demonstrated Marketability An adjunctive or alternative therapy to pain killers, including narcotics About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
How to Order an ActiPatch®?
Visit tryactipatch.com to place your order for the ActiPatch® today.
The Company We are the makers of ActiPatch Therapy, RecoveryRx Devices, HealFast Therapy and the Allay family of inexpensive, disposable drug-free anti-inflammatory devices.
Our revolutionary line of pain treatment products is sold in more than 35 countries, with the simple goal of changing the way people heal.
What is ActiPatch®? Recognized by the Wall Street Journal as one of the top medical innovations of 2009, ActiPatch® delivers its patented BioDynamic Therapy to not only relieve your pain, but to HEAL it so it doesn't come back. Drugs and heat patches don't work to cure your pain - they simply mask it. It always comes back. Introducing a breakthrough in pain relief!
How does ActiPatch® work?
When cells are damaged, inflammation sets in resulting in pain, swelling, and reduced cellular energy. ActiPatch® calms the inflammation and restores cells to their normal energy levels. The result: your pain and swelling diminish and your damaged cells actually begin to heal for sustained relief. For more information visit the Technology section of our website. Is ActiPatch® Safe? ActiPatch® is extremely safe and comfortable to wear. The low-level current that is gently pulsed into damaged tissue is undetectable, even though the device is continuously working to help you heal.
BIEL Primary Product — ActiPatch USPTO Patents - check Up to date - check FDA - partially OTC cleared foot and knee - check FDA - working with company on back clearance - check Trial supporting back clearance - finished - check FDA asked for back data pre-submission meet - check FDA relationship quality - fine Signed deals with large U.S. distributors - check, do DD Ongoing discussions with large U.S. retailers - check, do DD ActiPatch OTC cleared 50+ countries - check UK NHS Tariff approved for reimbursement - check NHS support - trial data, efficacy, safety, price NHS motives - public safety, efficacy, savings £100’s millions annually Launch - Publicly announced April 1, 2018 Post-launch ramp-up, 90 days NHS coverage - 100% insured patients with Rx Estimated price on NHS Rx launch - $ .009 to $ .02 Estimated price on FDA OTC Back clearance - $ .04 to $ .06 Estimated price on FDA OTC General clearance - $ .075 to $ .09 Estimated price on U.S. retail (CVS, Walgreens) launch - $ .11 to $ .15
Is most of this factual? You bet Is some of it speculative? You bet p.s. ActiPatch is the only miniaturized, USPTO patented, drug-free, side-effect free, safe and efficacious (FDA says so), partially FDA OTC cleared, pain management device in the world and it works well. Fact
The UK's leading pharmacy-led health and beauty retailer Boots UK is a member of Alliance Boots, an international pharmacy-led health and beauty group.
Our purpose is to help our customers look and feel better than they ever thought possible. We have close to 2,500 stores from local community pharmacies to large destination health and beauty stores. We offer fantastic products and services and you'll be cared for by expert, friendly people. http://www.boots-uk.com/
Disclaimer: This Un-Official BIEL Message Board was created by shareholders of BIEL for Shareholders of BIEL. The intent of this board is to help shareholders and also bring discussions about BIEL to a central place. Information above is gathered from either the internet or from other sources that could prove to be unreliable. Please do your own Due Diligence as some information may be out of date. IHub and the Moderators of this board (BIEL) will not claim nor hold any responsibility for a person(s) financial decisions. If any in-valid information is located on the BIEL board, please notify one of the moderators immediately so corrections can be made. Options: Sign up for 'Bioelectronics Corp.' E-Mail List